Topamax 25mg 28 capsules — Made in Italy — Free Delivery

As monotherapy for the treatment of adults and children over 6 years of age with partial seizures with or without secondary generalized seizures and primary generalized tonic-clonic seizures. As adjunctive therapy for the treatment of adults and children over 2 years of age with partial seizures with or without secondary generalized seizures or primary generalized tonic-clonic seizures and for the treatment of seizures associated with Lennox-Gastaut syndrome. For the prevention of migraine attacks in adults, after careful evaluation of alternative treatments. Topiramate is not recommended for the treatment of acute conditions.

Hypersensitivity to the components of the preparation. Prevention of migraine in pregnant women and women of reproductive age, unless they use effective methods of contraception.

active ingredient: topiramate; 1 capsule contains topiramate 25 mg or 50 mg excipients: sucrose, povidone, cellulose acetate, gelatin, purified water, sorbitan monolaurate, sodium lauryl sulfate, titanium dioxide (E 171), shellac glaze solution in ethanol, black iron oxide (E172), butyl alcohol, isopropyl alcohol, propylene glycol, ammonium hydroxide.

Treatment is recommended to start with a low dose, followed by a gradual selection of an effective dose. The dose and level of its increase should be selected depending on the clinical response. Topamax capsules can be swallowed whole or gently open the capsule and pour its contents onto a small amount (teaspoon) of soft food. The medicinal product/mixture should be swallowed immediately without chewing. Do not store the mixture of the contents of the capsule with food for later use. The preparation can be taken regardless of the meal. Control of topiramate plasma concentrations is not necessary to optimize Topamax treatment. In rare cases, the appointment of topiramate as an additional therapy in the treatment of phenytoin may require adjustment of the dose of phenytoin to achieve optimal clinical effect. The addition or withdrawal of phenytoin or carbamazepine as adjunctive therapy to Topamax may require dose adjustment of Topamax. Differentiation of antiepileptic preparations, including topiramate, should be implemented gradually in order to minimize the possibility of seizures or increase their frequency, regardless of whether patients had a history of epileptic seizures. During clinical studies, daily doses were reduced by 50-100 mg at weekly intervals in adults with epilepsy, and by 25-50 mg in adults taking topiramate at a dose of up to 100 mg per day for the prevention of migraine. In clinical studies involving children, the difference between topiramate was carried out gradually, over 2-8 weeks. monotherapy for epilepsy. When discontinuing concomitant antiepileptic preparations  for the purpose of topiramate monotherapy, the possible impact of this step on the frequency of seizures should be considered. If safety considerations do not require urgent discontinuation of the concomitant antiepileptic preparation, a gradual dose reduction by 1/3 every 2 weeks is recommended. With the abolition of preparations  that are inducers of liver enzymes, the concentration of topiramate in the blood will increase. In such situations, if there are clinical indications, the dose of Topamax can be reduced.